Clinical trial
The Effect of Subconjunctival Aflibercept on Regression of Corneal Neovascularization
NCT02797704 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Subconjunctival Aflibercept on Regression of Corneal Neovascularization
- Lead sponsor
- Rabin Medical Center
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- March 2, 2017
- Completion date
- September 10, 2019
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.